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ABSTRACT Isavuconazole is the newest medical azole. We investigated EUCAST
MICs for isavuconazole and seven comparators against 1,498 contemporary isolates
(2016 to 2017). EUCAST susceptibility testing was performed. Isavuconazole MICs 2
dilution steps above the modal MIC were regarded as non-wild type for species
without EUCAST epidemiological cutoff values (ECOFFs). CYP51A sequencing was
performed when relevant. Pearson correlation analysis was adopted for comparing
activity. Aspergillus accounted for 90% of mold and Candida accounted for 97% of
yeast isolates. Thirty (9.3%) Aspergillus fumigatus isolates were classiﬁed as resistant,
and 10 (3.1%) were classiﬁed as non-wild type. Thirteen (4%) were cross-resistant to
other mold-active azoles. Target gene alterations were found in 10 (76.9%) isolates,
including 4 (30.8%) of environmental origin (TR34/L98H [n 3] and Trip343/L98H
[n 1]). Six Aspergillus terreus isolates were resistant, including two (17%) with MICs
of 2 mg/liter and M217I alterations. Modal MICs/MIC50s (milligrams per liter)
against Candida spp. were 0.004/0.004 for C. albicans and C. dubliniensis, 0.008/
0.008 for C. tropicalis, 0.016/0.016 for C. parapsilosis, 0.06/0.06 for C. glabrata, and
0.125/0.125 for C. krusei. A non-wild-type phenotype was observed for 6.6% of iso-
lates (C. glabrata [11.8%] and C. tropicalis [12.3%], speciﬁcally). All of these isolates
were nonsusceptible/non-wild type to ﬂuconazole (96.1%) or voriconazole (86.2%).
Low MICs were found for several other species, except Scedosporium apiospermum
and Fusarium. The best correlation was found between isavuconazole and voricona-
zole overall but for A. terreus and Mucorales to itraconazole and posaconazole, re-
spectively. Isavuconazole displayed broad in vitro activity. Acquired resistance was
infrequent except in A. terreus, C. glabrata, and C. tropicalis and, when present, was
associated with cross-resistance to other azoles. Revising the EUCAST breakpoints for
A. fumigatus (deﬁning an MIC of 2 mg/liter as intermediate [“I”]) would minimize ma-
jor errors.
KEYWORDS Aspergillus, Candida, EUCAST, Mucorales, antifungal susceptibility
testing, azoles
Isavuconazole is the newest medical azole with activity against a broad range of yeastand molds. It was licensed in Europe and the United States in 2015 by the EMA and
FDA for the treatment of adults with invasive aspergillosis and also for mucormycosis
although by the EMA only in patients for whom amphotericin B is inappropriate. In the
same year, EUCAST clinical breakpoints were established for three Aspergillus species (A.
fumigatus, A. nidulans, and A. terreus), and epidemiological cutoff values (ECOFFs) for
these as well as for A. ﬂavus and A. niger were determined (1). Isavuconazole given daily
or weekly has also been found efﬁcacious and noninferior to ﬂuconazole for uncom-
plicated esophageal candidiasis in a randomized, double-blind, multicenter phase 2
trial, where Candida albicans was the most common cause of infection, accounting for
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94.8% (2). In line with this in vivo efﬁcacy, isavuconazole has potent in vitro activity
against particularly C. albicans, C. parapsilosis, and C. tropicalis, with an MIC of
0.03 mg/liter for 91.5% to 96.0% of such isolates (3). MICs against C. glabrata and C.
krusei are higher, with modal MICs of between 0.03 mg/liter and 0.5 mg/liter in most
data sets (3–6). Unfortunately, EUCAST ECOFFs and breakpoints have not been estab-
lished for Candida species due to signiﬁcant interlaboratory variability (3).
Previous studies have shown a correlation between the susceptibility to the azoles
and, particularly, the susceptibility to voriconazole and isavuconazole for A. fumigatus
(7, 8). Similarly, studies have shown that isavuconazole susceptibility was lower for
Candida isolates with resistance or non-WT (wild-type) susceptibility to ﬂuconazole and
voriconazole (9).
Denmark is a high-incidence country for candidemia, with a high use of antifungal
compounds, including azoles, in a Nordic perspective (10). Hence, it is of utmost
importance to monitor the susceptibility proﬁles of clinically relevant fungal isolates. In
this study, we investigated and compared the in vitro activities of isavuconazole and
seven comparators against a large contemporary clinical collection of mold and yeast
isolates received at the Danish mycology reference center during the years 2016 to
2017. MICs were interpreted by applying recently established EUCAST clinical break-
points and ECOFFs.
RESULTS
During 2016 and 2017, isavuconazole susceptibility was determined for 429 mold
isolates and 1,069 yeast isolates from 1,325 patients. The MICs for isavuconazole and
comparators (voriconazole, itraconazole, posaconazole, and amphotericin B for molds
and voriconazole, ﬂuconazole, amphotericin B, anidulafungin, and micafungin for
yeasts) were evaluated separately for 2016 and 2017, but as no difference was seen for
the 2 years (modal MICs and MIC50s within 1 dilution step [data not shown]), data
were pooled and are presented together.
Molds. Aspergillus accounted for 90.2% (n 387) of the 429 mold isolates (Table 1).
Adopting the EUCAST ECOFFs available for the ﬁve most prevalent Aspergillus complex
TABLE 1MICs and geometric mean MICs of isavuconazole against the 429 mold isolates
Isolate category
Total no.
of isolates
No. of S
isolatesa
No. of isolates with MIC (mg/liter) ofh:
MIC range
(mg/liter)
Modal MIC
(mg/liter)
MIC50
(mg/liter)
Geometric
mean MIC
(mg/liter)<0.125 0.25 0.5 1 2 4 8 16 >16
All Aspergillus 387 232 1 4 25 53 38 13 14 7 0.125 to 16
Most prevalent Aspergillus
A. ﬂavus complex 16 2 7 6 1 0.5 to 4 1 1 1.30
A. fumigatus 322 232 1 1 18 40 20 1 5 4 0.125 to 16 1 1 1.25
A. nidulans complexb 3 2 1 0.25 to 0.5
A. niger complexc 26 2 7 9 7 1 1 to 16 4 4 3.79
A. terreus 12 3 3 4 2 0.5 to 16 2 1 1.68
Other Aspergillusd 8 1 1 1 1 2 2 0.25 to 8
Fusariume 14 1 13 16 to 16
Dermatophytesf 9 5 2 1 1 0.125 to 2
Mucoralesg 16 1 1 4 3 3 4 0.25 to 16
aNumber of isolates sensitive to itraconazole, posaconazole, and voriconazole determined by azole agar screening.
bOne isolate each of the A. nidulans complex, A. quadrilineatus, and A. spinulosporus.
cTwenty-two isolates of the A. niger complex, three isolates of A. tubingensis, and one of A. luchuensis.
dThree A. calidoustus isolates and one isolate each of A. ﬁscheri, A. giganteus, A. persii, A. similis, and A. turcosus.
eTwo F. dimerum, two F. proliferatum, seven F. solani sensu stricto, and three F. solani complex isolates.
fTwo M. canis, four T. rubrum, one T. interdigitale, and two T. mentagrophytes complex isolates.
gTwo M. circinelloides isolates, three R. pusillus isolates, four R. microsporus isolates, and one isolate each of C. muscae, L. corymbifera, L. ramosa, Lichtheimia species,
R. oryzae, Syncephalastrum racemosum, and Mucorales species.
hResistant Aspergillus isolates are shaded, and non-wild-type isolates are shown in boldface type.
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isolates, 24 (6.4%) were non-wild type, and among the three species for which clinical
breakpoints have been established, 36/335 (10.7%) isolates were classiﬁed as resistant
(R). In detail, 30/322 (9.3%) A. fumigatus isolates (from 28 patients) were classiﬁed as
resistant, and 10/322 (3.1%) from 9 patients were classiﬁed as non-wild type. Three
(15%) A. fumigatus isolates with isavuconazole MICs of 2 mg/liter (classiﬁed as resistant
but within the wild-type range) were cross-resistant to itraconazole (MIC 16 mg/liter).
Two of these isolates harbored Cyp51A alterations and were also cross-resistant to
either posaconazole and voriconazole (G54A; MICs of 4 mg/liter and 2 mg/liter,
respectively) or posaconazole only (M220K; MIC of 4 mg/liter). All 10 A. fumigatus
isolates with MICs of 2 mg/liter (and, thus, both resistant and non-wild type) were
nonsusceptible to itraconazole, posaconazole, and voriconazole. Eight of these isolates
(80%) harbored Cyp51A alterations (TR34/L98H [n 3], Trip343/L98H [n 1], TR120/
F46Y/M172V/E427K [n 1], G432S [n 1], and G448S [n 2]). Thus, overall, 13/322
(4%) of the A. fumigatus isolates were classiﬁed as isavuconazole resistant and cross-
resistant to other mold-active azoles, and 10/13 (76.9%) harbored target gene altera-
tions, including 4/13 (30.8%) whose alterations were due to an environmental resis-
tance mechanism.
Six A. terreus (50%) isolates from ﬁve patients were classiﬁed as isavuconazole
resistant and non-wild type, including 4/4 isolates with MICs of 2 mg/liter, the wild-type
CYP51A target gene, and susceptibility to the other three azoles. The remaining two
isolates (17%), with an isavuconazole MIC of 2 mg/liter, harbored an M217I alteration
(corresponding to the M220I alteration in A. fumigatus).
Finally, among other molds, low MICs (0.25 mg/liter) were observed against
Microsporum canis, Trichophyton rubrum, Trichophyton interdigitale, Circinella muscae,
and Saprochaete capitata, and high MICs (16 mg/liter) were observed against Sce-
dosporium apiospermum, Fusarium spp. (including F. dimerum, F. proliferatum, and F.
solani complex isolates), and 4/16 Mucorales isolates (Mucor circinelloides [n 3] and
Rhizopus oryzae). However, numbers were low.
The in vitro activity of isavuconazole against A. ﬂavus, A. fumigatus, A. nidulans, and
A. terreus isolates on a milligram-per-liter basis was comparable to those of voricona-
zole and amphotericin B and slightly lower than those of itraconazole and posacona-
zole (Table 2). For A. niger isolates, the isavuconazole modal MIC and MIC50 were two
2-fold dilutions higher than those for voriconazole and itraconazole and four 2-fold
dilutions higher than those for posaconazole and amphotericin B. As isavuconazole and
the comparators are all regarded as valid options for A. fumigatus infections, the
proportions of isolates with MICs above the ECOFF against A. fumigatus were compared
for each compound as an indicator of relative coverage (Table 2). The proportions of A.
ﬂavus and A. terreus isolates with MICs above the A. fumigatus ECOFF were lower for
isavuconazole than for amphotericin B and voriconazole, whereas in contrast, the
proportion of A. niger isolates less susceptible than A. fumigatus was highest for
isavuconazole (Table 2).
Yeast. Candida accounted for 97.2% (n 1039) of the 1,069 yeast isolates (Table 3).
Other species were Saccharomyces cerevisiae (12; 1.1%), Cryptococcus neoformans (10;
0.9%), and rare yeast (8; 0.7%). Overall, 91% of MICs fell at 0.125 mg/liter, and 95%
were 0.25 mg/liter.
The vast majority of the MICs against the most susceptible Candida species fell at or
below the lowest concentrations tested (Table 3), i.e., for C. albicans, 417/438 (95.2%)
overall and 250/264 (94.7%) for the extended concentration range, speciﬁcally, and for
C. dubliniensis, 53/57 (93.0%) and 29/33 (87.9%), respectively. Consequently, modal MIC
and MIC50 values were 0.004 mg/liter. For the other common Candida species, the
modal MIC/MIC50 values (milligrams per liter) were as follows: 0.008/0.008 for C.
tropicalis, 0.016/0.016 for C. parapsilosis, 0.06/0.06 for C. glabrata, and 0.125/0.125 for C.
krusei. In all cases, the modal MIC and MIC50 values set using the 11-dilution range were
supported by the 8-dilution range adopted in the ﬁrst part of the study period,
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suggesting a robust performance of EUCAST isavuconazole testing during the study
period.
For 65/979 (6.6%) isolates from these six most prevalent Candida species (iso-
lated from 60 patients), an isavuconazole MIC 2 dilution steps above the modal
MIC for a given species (2 dilutions if the modal MIC fell at the lowest concen-
tration tested [0.004 mg/liter]) could be documented, suggesting a non-wild-type
phenotype (indicated with gray shading in Table 3). In detail, this was the case for
14/438 (3.2%) C. albicans, 3/57 (5.3%) C. dubliniensis, 38/322 (11.8%) C. glabrata,
1/54 (1.9%) C. krusei, 1/43 (2.3%) C. parapsilosis, and 8/65 (12.3%) C. tropicalis
isolates. When ﬂuconazole and voriconazole susceptibilities were investigated for
these isolates, 96.1% were nonsusceptible/non-wild type to ﬂuconazole, 86.2%
were nonsusceptible/non-wild type to voriconazole, and all were nonsusceptible/
non-wild type to at least one of the two (data not shown). For C. glabrata, 13/38
(34.2%) of the isavuconazole non-WT isolates presented ﬂuconazole MICs of
16 mg/liter, rendering classiﬁcation as intermediate (I) or R impossible. One of
these isolates was voriconazole susceptible (S), whereas the remaining 12 were
classiﬁed as voriconazole non-WT.
The rare Candida species were characterized by isavuconazole MICs spanning the
entire 0.004- to 4-mg/liter concentration range, suggesting differential susceptibil-
ities of the involved species. The most resistant species was C. duobushaemulonii
(n 1), with an MIC of 4 mg/liter, whereas the single C. auris isolate, originating from
a Norwegian patient, as well as isolates belonging to C. bovina, C. famata, C. kefyr, C.
metapsilosis, C. nivariensis, C. palmioleophila, C. pararugosa, C. pelliculosa, and C. utilis
had isavuconazole MICs of 0.06 mg/liter. Similarly, the MICs for rare yeast were
diverse, with Magnusiomyces capitatus being the isolate with the highest isavuconazole
MIC of 2 mg/liter.
On a milligram-per-liter basis, the in vitro activity of isavuconazole was more similar
to that of voriconazole against the yeast isolates than to that of ﬂuconazole and similar
to that of the echinocandins, except for C. parapsilosis, Cryptococcus, C. glabrata, and C.
krusei (Table 4).
Correlation between susceptibilities to isavuconazole and comparators. Finally,
the correlation between isavuconazole and comparator MICs was investigated
(Table 5). A signiﬁcant correlation was observed between isavuconazole and vori-
conazole MICs for all mold and Candida species, although it was weak (R2 of 0.5
for Mucorales, C. krusei, and C. parapsilosis). Moreover, the correlation between
isavuconazole and voriconazole was stronger than that between isavuconazole and
any other comparator for all species except A. terreus and Mucorales species (the
best correlation was observed for isavuconazole and posaconazole). A good and
highly signiﬁcant correlation was also observed between isavuconazole and ﬂu-
conazole for C. albicans, C. glabrata, and C. tropicalis but not for C. parapsilosis.
DISCUSSION
This study conﬁrmed previous ﬁndings of potent in vitro activity of isavuconazole
against most human-pathogenic fungi (3–5, 9, 11). The rate of acquired resistance in
Aspergillus and Candida spp. was overall low and stable (4). Exceptions were resistance
rates of around 10% in A. fumigatus, A. terreus, C. glabrata, and C. tropicalis. However,
resistance rates may be overestimated, as fungal isolates referred to a reference
laboratory may not be representative of the general population. For the two Aspergillus
species, however, the resistance was in part due to a stringent susceptibility breakpoint
bisecting the wild-type populations of A. fumigatus and A. terreus, leading to a mis-
classiﬁcation of some susceptible isolates as resistant. The ECOFF for isavuconazole
against A. fumigatus is 2 mg/liter, but the clinical breakpoint established was one step
lower because isolates with an MIC of 2 mg/liter may represent isolates with wild-type
as well as mutant target gene sequences (1, 3). Thus, in a multicenter study, MICs
straddled the ECOFF, with MICs of 2 mg/liter found in 25% of isolates harboring the
M220I and M220V mutations and in 72.5% of the MIC readings of isolates withTR34/
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L98H alterations, suggesting a slight and more prominent reduction of susceptibility.
The majority of the A. fumigatus isolates classiﬁed as wild type but resistant due to an
MIC of 2 mg/liter in the present study had no cross-resistance to other azoles and no
target gene alterations. Moreover, one isolate was voriconazole susceptible and har-
bored the M220K alteration, which previously has been shown not to affect isavucona-
zole susceptibility (3). Finally, one strain harbored a G54A alteration and was voricona-
zole intermediate. Whereas isavuconazole susceptibility in strains harboring G54E,
G54R, G54V, or G54W alterations appears unaffected, to our knowledge, it is not known
if G54A may affect isavuconazole and voriconazole susceptibility (3). Hence, our data
suggested that the majority of isolates with an MIC of 2 mg/liter will be true wild-type
isolates, and the remaining minority will be characterized by slightly reduced isavu-
conazole susceptibility. Buil et al. found that the probability of target attainment for
isolates with isavuconazole MICs of 2 mg/liter with the isavuconazole standard dose
was75% (64% to 92%) when the 90% exposure index (EI90) was used as the endpoint
and that a trough level of 1.60 mg/liter (1.42 to 1.80 mg/liter) was the target (8).
Another recent study reported that approximately 10% of “real-life” clinical samples
contained less than 1 mg/liter and another approximately 20% contained between 1
and 2 mg/liter of isavuconazole (12). Taken together, these observations support
introducing an intermediate category for A. fumigatus and A. terreus isolates with an
MIC of 2 mg/liter in a setting where therapeutic drug monitoring is available to conﬁrm
sufﬁcient exposure.
When the correlations between isavuconazole MICs and those for the comparators
were analyzed, the strongest correlation overall was found for isavuconazole and
voriconazole. Thus, a signiﬁcant strong to moderate correlation was found for the four
most common Aspergillus species as well as for the six most common Candida species
except C. krusei and C. parapsilosis, for which the correlation was signiﬁcant but weak
(R2 of 0.417 to 0.448), potentially due to the lack of isolates with acquired resistance for
these two species. Thus, our results extend previous ﬁndings of a correlation between
the azoles and, particularly, voriconazole and isavuconazole for A. fumigatus (7, 8) and
the ﬁndings that isavuconazole susceptibility was lower for Candida isolates with
resistance or non-wild-type susceptibility to ﬂuconazole and voriconazole (9). No
correlation was found for isavuconazole compared to itraconazole or posaconazole for
A. ﬂavus or A. fumigatus. For A. fumigatus, this may not be surprising, as it is well
acknowledged that some target gene mutations speciﬁcally affect itraconazole and
posaconazole (3). For A. ﬂavus, we assume that the absence of isolates with differential
TABLE 5 Correlation between isavuconazole MICs and those of voriconazole, itraconazole, posaconazole, and amphotericin Ba
Species
Voriconazole Itraconazole Posaconazole Fluconazole Amphotericin B
No. of
isolatesbR2 P R2 P R2 P R2 P R2 P
A. ﬂavus 0.598 0.0004 0.090 0.2581 0.196 0.086 ND ND 0.229 0.0608 16
A. fumigatus 0.766 0.0001 0.289 0.0001 0.071 0.0115 ND ND 0.003 0.6276 89
A. niger 0.573 0.0001 0.537 0.0002 0.225 0.0177 ND ND 0.0414 0.3405 21–24
A. terreus 0.740 0.0003 0.763 0.0004 0.807 0.0002 ND ND 0.585 0.0038 10–12
Mucorales 0.381 0.0108 0.072 0.3336 0.691 0.0001 ND ND 0.101 0.2291 15–16
C. albicans 0.896 0.0001 ND ND ND ND 0.786 0.0001 0.0215 0.4564 9–28
C. dubliniensis 0.938 0.0015 ND ND ND ND 0.857 0.008 0.675 0.0234 6–7
C. glabrata 0.862 0.0001 ND ND ND ND 0.817 0.0001 0.0092 0.1361 216–244
C. krusei 0.417 0.0001 ND ND ND ND 0.207 0.0008 0.0146 0.3983 51
C. parapsilosis 0.448 0.0002 ND ND ND ND 0.00871 0.6573 0.0934 0.1289 25–26
C. tropicalis 0.786 0.0001 ND ND ND ND 0.668 0.0001 0.0679 0.1306 33–35
Other Candida 0.514 0.0001 ND ND ND ND 0.439 0.0001 0.000464 0.8845 42–48
aThe strongest correlation (highest R2 coefﬁcient) for each species across the four comparators is highlighted in boldface type, and signiﬁcant P values are underlined.
ND, not done.
bNumber of paired values for comparison (isolates with MICs below the lowest concentration were excluded from analyses, whereas isolates with MICs above the
concentration range were elevated to the nearest higher 2-fold dilution).
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susceptibility explains the lack of correlation because MIC variation in such cases can be
explained solely by test variation. Therefore, taken together, our data support that
voriconazole susceptibility is a strong marker of isavuconazole susceptibility in most
clinically relevant Candida and Aspergillus isolates. Of note, this suggests that the azole
agar screening method (EUCAST E.Def 10.1) can be adopted for identiﬁcation of A.
fumigatus isolates suitable as targets for isavuconazole therapy despite the fact that an
isavuconazole agar is not included in the plate design (13).
Isavuconazole is licensed as a second-line option for the treatment of Mucorales
infections in adults after the VITAL study showed equal clinical efﬁcacy compared to
that for matched historical controls treated with amphotericin B (14). In that study,
species-speciﬁc outcome evaluation was not performed, probably in part because
one-third of the cases lacked species identiﬁcation. We found consistently high MICs of
16 mg/liter for M. circinelloides, conﬁrming previous ﬁndings by CLSI and EUCAST
testing (15, 16). Hence, species identiﬁcation is highly recommended, as clinical efﬁcacy
remains to be conﬁrmed for this species.
Isavuconazole is not licensed for the treatment of invasive candidiasis after a recent
phase 3, randomized, double-blind, multinational clinical trial failed to demonstrate
noninferiority at the end of intravenous (i.v.) therapy compared to caspofungin (17).
Thus, the trial supported the results of other clinical studies showing superiority of
echinocandins over azoles and amphotericin B and, thus, the recommendation of
echinocandins as ﬁrst-line agents for candidemia and invasive candidiasis (18–21).
Nevertheless, the secondary endpoints (overall response to therapy 2 weeks after the
end of therapy and all-cause mortality on days 14 and 56) were similar between arms,
as were safety and median time to clearance from the bloodstream. On this background
and taking the potent in vitro activity and attractive safety proﬁle compared to
ﬂuconazole and voriconazole into account, isavuconazole might serve as a valid
second-line option in settings where echinocandin resistance is likely or documented,
mold coverage is indicated, or oral therapy is preferred.
In summary, isavuconazole displayed broad in vitro activity against most human-
pathogenic species, including dermatophytes and several uncommon species. Of note,
however, we conﬁrmed low isavuconazole in vitro activity against M. circinelloides and
therefore advocate for performing species identiﬁcation, also for Mucorales, whenever
possible. Acquired isavuconazole resistance was infrequent, except in A. terreus, C.
glabrata, and C. tropicalis, and, when present, was associated with cross-resistance to
other azoles. Continued surveillance remains important.
MATERIALS AND METHODS
Isolates. In total, 1,069 yeast and 429 mold isolates from 1,325 patients were included (1 isolate each
from 1,186 patients and 2 to 7 isolates from 139 patients). The isolates were prospectively obtained from
clinical samples or pure cultures received at the mycology reference laboratory at Statens Serum Institut
for identiﬁcation and susceptibility testing during 2016 and 2017. No ethical restraints apply to studies
of routinely obtained anonymized laboratory data. Same-species isolates from the same patient were
excluded from the study if sampled 21 days apart and identical MICs (within 1 dilution step) were
seen. The isolates derived from the entire country and the following clinical specimens: blood as part of
the national surveillance program (915 specimens), airways/lung/pleura/sinus (404), other normally
sterile sites (47), urine (20), skin/scalp/nail (24), cervix/vagina/urethra (13), other superﬁcial sites (39), and
other/unspeciﬁed (36). Yeast identiﬁcation was done using macro- and micromorphology, supplemented
by thermotolerance (incubation at 37°C and 43°C), matrix-assisted laser desorption ionization–time of
ﬂight mass spectrometry (Bruker, Bremen, Germany) for Candida (22), and, when needed, internal
transcribed spacer (ITS) sequencing (23). Similarly, mold identiﬁcation was done by classical techniques,
including thermotolerance (incubation at 50°C) for discriminating A. fumigatus sensu stricto from cryptic
species, which underwent -tubulin sequencing (24). The use of the term “complex” is acknowledged for
Aspergillus species other than A. fumigatus, in the absence of detailed molecular identiﬁcation, although
for simplicity, it is not used throughout this work. ITS and TEF (transcription elongation factor) sequenc-
ing were adopted for other molds and Fusarium species, speciﬁcally (23, 25).
Susceptibility testing. EUCAST susceptibility testing was performed according to E.Def 7.3.1 for
yeast. Isavuconazole and amphotericin B MICs were determined for all 1,069 yeast isolates, voriconazole
and ﬂuconazole MICs were determined for 1,068/1,069 (99.9%) isolates, micafungin MICs were deter-
mined for 1,066/1,069 (99.7%) isolates, and anidulafungin MICs were determined for 1,064/1,069 (99.5%)
of the yeast isolates. For the molds, A. fumigatus isolates were screened for azole resistance according to
EUCAST E.Def 10.1 using a four-well plate containing RPMI 1640–2% glucose agar supplemented with
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itraconazole (4 mg/liter), voriconazole (1 mg/liter), posaconazole (0.5 mg/liter), and no antifungal (posi-
tive control) (Balis Laboratorium VOF, Boven-Leeuwen, the Netherlands). In brief, 25 l of a conidial
suspension (ﬁltered through an 11-nm ﬁlter) at a 0.5 McFarland standard was added to each well, and
the plate was incubated for 48 h at 37°C before reading. Screening of agar-positive A. fumigatus isolates
and all other molds was performed according to EUCAST E.Def 9.3.1, with standard ﬁltration (11-nm ﬁlter)
of the inoculum. Isavuconazole and voriconazole susceptibilities were determined for all 429 mold
isolates, posaconazole susceptibility was determined for 428/429 (99.8%) isolates, and itraconazole and
amphotericin B susceptibilities were determined for 427/429 (99.5%) of the mold isolates. Stock solutions
of the following antimycotics were prepared at 5,000 mg/liter in dimethyl sulfoxide (Sigma-Aldrich,
Brøndby, Denmark): isavuconazole (Basilea Pharmaceutica Ltd., Basel, Switzerland), voriconazole (Pﬁzer,
Ballerup, Denmark), itraconazole (Sigma-Aldrich), posaconazole (MSD, Ballerup, Denmark), ﬂuconazole
(Sigma), amphotericin B (Sigma), anidulafungin (Pﬁzer, Ballerup, Denmark), and micafungin (Astellas,
Tokyo, Japan). Cell culture-treated microtiter polystyrene plates (Nunc microwell 96-well microplates,
catalog no. 167008; Thermo Fisher Scientiﬁc) were used throughout. Candida krusei ATCC 6258 and
Candida parapsilosis ATCC 22019 were used as controls for the yeasts, and Aspergillus ﬂavus ATCC 204304
and Aspergillus fumigatus ATCC 204305 were used as controls for the molds. For the yeast isolates, during
the study period, the concentration range was extended from 8 to 11 dilutions. CYP51A sequencing was
performed for non-wild-type/resistant A. fumigatus and A. terreus isolates.
Data analysis. Modal MICs, MIC50s, geometric mean MICs (GM-MICs), and MIC ranges were deter-
mined for individual species (n  10). EUCAST ECOFFs/breakpoints were adopted for wild-type/suscep-
tibility classiﬁcation. For species without EUCAST ECOFFs, MICs 2 dilution steps above the modal MIC
were regarded as non-wild type. However, for species where the modal MIC was equal to or lower than
the lowest concentration tested, MICs2 dilution steps above the modal MIC were regarded as non-wild
type. Pearson correlation analyses with a two-tailed P value were performed for comparisons of
antifungal in vitro activities (after log2 transformation) using GraphPad Prism 7.04. Correlation coefﬁcients
(squared) (R2) of 0.5 with a P value 0.05 were interpreted as a signiﬁcant indicator of good to strong
correlation, whereas R2 values of 0.5 indicated weak correlation.
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